Home › Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies
 

Keywords :   


Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies

2015-06-01 14:30:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. & BERKELEY, Calif. Studies to Evaluate the Combination of Dynavaxs SD-101 with Two Immunotherapies from Mercks Pipeline, KEYTRUDA (pembrolizumab) and MK-1966 Collaboration Includes First-in-human Study for MK-1966, a New Investigational Anti-interleukin-10 (anti-IL-10) Immunomodulator from Mercks Rapidly Growing Immuno-oncology Pipeline KENILWORTH, N.J. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orMerck Investor Relations:Justin Holko, 908-740-1879orDynavax Investor/Media Relations:Michael Ostrach, 510-665-7257 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: combination collaboration announce investigating

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.06US surgeon general wants social media warning labels
17.06Topigs Norsvin unveils new boar test and research center
17.06Pork producers lead freedom to farm defense
17.06Eastern North Pacific Tropical Weather Outlook
17.06Atlantic Tropical Weather Outlook
17.06Labour accuses Tories of planning unfunded tax cuts
17.06Petrol prices far higher than they should be, says RAC
17.06Farm Progress America, June 17, 2024
More »